chartexchange

Zura Bio discontinues tibulizumab in HS after Phase II trial failure

Clinical Trials Arena | Nov 10, 2026 4:59 AM EST

Zura Bio has discontinued the clinical development of tibulizumab in HS after the Phase II TibuSHIELD trial failed to meet its endpoints.
The post Zura Bio discontinues tibulizumab in HS after Phase II trial failure appeared first on Clinical Trials Arena .

Read original article